Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer.
Two topotecan treatment schedules in patients with recurrent epithelial ovarian cancer were evaluated. Protocol A (21 days) was 1.5 mg/m(2)/day topotecan on days 1 through 5 of a 21-day cycle; Protocol B (weekly) 4 mg/m(2) on days 1, 8, and 15 of a 28-day cycle. Efficacy was determined by clinical exam, CT scan, and CA125 levels. Forty-three patients on Protocol A and 21 on Protocol B were evaluated. As second-line treatment, Protocol A response was 9/20 (45%). Response to Protocol B was 4/17 (23.5%; NS). As third line or more, the response on Protocols A and B together was only 3/27 (11%). High-grade haematological toxicity was reported in 12/43 (27.9%) on Protocol A and 1/21 (4.8%) on Protocol B (p = 0.04). There was no difference in progression-free-intervals between schedules in second-line treatment. The weekly protocol had lower severe haematological toxicity. Clinical response in third line or more was very low.
a Division of Gynecologic Oncology , Meir Medical Center , Kfar Saba , Israel.|b Sackler School of Medicine , Tel Aviv University , Tel Aviv , Israel.
Ilan
I
Bruchim
a Division of Gynecologic Oncology , Meir Medical Center , Kfar Saba , Israel.|b Sackler School of Medicine , Tel Aviv University , Tel Aviv , Israel.
Zipi
Z
Ben-Harim
a Division of Gynecologic Oncology , Meir Medical Center , Kfar Saba , Israel.|b Sackler School of Medicine , Tel Aviv University , Tel Aviv , Israel.
Ettie
E
Piura
a Division of Gynecologic Oncology , Meir Medical Center , Kfar Saba , Israel.|b Sackler School of Medicine , Tel Aviv University , Tel Aviv , Israel.
Gabi
G
Haran
a Division of Gynecologic Oncology , Meir Medical Center , Kfar Saba , Israel.|b Sackler School of Medicine , Tel Aviv University , Tel Aviv , Israel.
Ami
A
Fishman
D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D059004:Topoisomerase I Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D019772:Topotecan / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D059004:Topoisomerase I Inhibitors; D019772:Topotecan
Chemotherapy; Epithelial ovarian cancer; Topotecan